Multiple Myeloma | eHealth News

For patients with newly diagnosed multiple myeloma

Study Supports Minimal Residual Disease As End Point in Myeloma

HealthDay.com - Sep 16, 2016 0

MRD-negative status linked to favorable progression-free, overall survival in multiple myeloma

$Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma$

Survival Up With Daratumumab in Relapsed Multiple Myeloma

HealthDay.com - Aug 24, 2016 0

Longer progression-free survival seen with daratumumab plus bortezomib and dexamethasone

1...6 78Page 8 of 8

Tag: Multiple Myeloma

Study Supports Minimal Residual Disease As End Point in Myeloma

Survival Up With Daratumumab in Relapsed Multiple Myeloma

EVEN MORE NEWS

FDA Says Shortage of GLP-1 Tirzepatide Is Over

FDA Updates Meaning of ‘Healthy’ on Food Labels

FDA Expands Approval of Vtama to Include Atopic Dermatitis

POPULAR CATEGORY